Search

everythinglearnresearchcommunity

for

Search:↓

Special cells can help regrow hair in alopecia areata.

Gefitinib can cause rare scarring hair loss.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Nivolumab can cause hair loss as a rare side effect.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Lotion with fucoidan from brown seaweed improved skin and reduced allergy symptoms in mice with dermatitis.

Antigen presenting cells around hair follicles are crucial in SLE-related hair loss.

Gut bacteria may influence hair loss in alopecia areata.

Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Early diagnosis and treatment of nail lichen planus in children can prevent permanent nail damage.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

PCOS is linked to inflammation, and certain markers could help in its treatment.

3D spheroid culture makes stem cells better at reducing inflammation.

Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.

The uric acid to creatinine ratio is a strong indicator for diagnosing PCOS.

Alopecia areata is an autoimmune disease with genetic links, treatable with certain medications, and can affect mental health.

Folliculotropic Mycosis Fungoides requires stage-based treatment, with early stages using skin therapies and advanced stages needing aggressive treatments.

Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.

Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.

Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Daylight photodynamic therapy is effective and well-tolerated for treating actinic keratoses with minimal side effects.

Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.

The combination therapy was effective and well-tolerated, especially in young patients.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.